Your Article Summary
See Latest ArticlesAntigenics Reports First Quarter 2009 Financial Results
Antigenics, 05/28/09
Antigenics Inc. reported results for the quarter ended March 2009. The company incurred a net loss attributable to common stockholders of $9.7 million, or $0.14 per share, basic and diluted, for the first quarter of 2009, compared with a net loss attributable to common stockholders in the first quarter of 2008 of $11.6 million, or $0.21 per share, basic and diluted. The company's net cash burn for the three months ended March 2009 and 2008 was $9.8 million and $9.4 million, respectively. The 2009 results reflect, among other things, the company's continued focus on supporting Oncophage in Europe and Russia. Cash, cash equivalents and short-term investments amounted to $24.6 million as of March 31, 2009.
Today in Financial Reports...keeping you current
Receive free subspecialty "5-minute updates" via email
Pre-Budget Report response - GSK comments on patent box
GlaxoSmithKline, 12/11/09
Report: Acquisition Activity Down
HealthDataManagement, 12/08/09
Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
Genzyme, 12/07/09